The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy

ABSTRACT Background The second consensus criteria for the diagnosis of multiple system atrophy (MSA) are widely recognized as the reference standard for clinical research, but lack sensitivity to diagnose the disease at early stages. Objective To develop novel Movement Disorder Society (MDS) criteri...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Movement disorders Ročník 37; číslo 6; s. 1131 - 1148
Hlavní autori: Wenning, Gregor K., Stankovic, Iva, Vignatelli, Luca, Fanciulli, Alessandra, Calandra‐Buonaura, Giovanna, Seppi, Klaus, Palma, Jose‐Alberto, Meissner, Wassilios G., Krismer, Florian, Berg, Daniela, Cortelli, Pietro, Freeman, Roy, Halliday, Glenda, Höglinger, Günter, Lang, Anthony, Ling, Helen, Litvan, Irene, Low, Phillip, Miki, Yasuo, Panicker, Jalesh, Pellecchia, Maria Teresa, Quinn, Niall, Sakakibara, Ryuji, Stamelou, Maria, Tolosa, Eduardo, Tsuji, Shoji, Warner, Tom, Poewe, Werner, Kaufmann, Horacio
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Hoboken, USA John Wiley & Sons, Inc 01.06.2022
Wiley Subscription Services, Inc
Predmet:
Atrophy
Brain - pathology
Consensus
Diagnosis
diagnostic criteria
Humans
Literature reviews
Magnetic Resonance Imaging
Medical diagnosis
Movement disorders
multiple system atrophy
Multiple System Atrophy - diagnosis
Multiple System Atrophy - pathology
Neuroimaging
Prospective Studies
Regular Issue
Review
diagnosis
diagnostic criteria
multiple system atrophy
ISSN:0885-3185, 1531-8257, 1531-8257
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:ABSTRACT Background The second consensus criteria for the diagnosis of multiple system atrophy (MSA) are widely recognized as the reference standard for clinical research, but lack sensitivity to diagnose the disease at early stages. Objective To develop novel Movement Disorder Society (MDS) criteria for MSA diagnosis using an evidence‐based and consensus‐based methodology. Methods We identified shortcomings of the second consensus criteria for MSA diagnosis and conducted a systematic literature review to answer predefined questions on clinical presentation and diagnostic tools relevant for MSA diagnosis. The criteria were developed and later optimized using two Delphi rounds within the MSA Criteria Revision Task Force, a survey for MDS membership, and a virtual Consensus Conference. Results The criteria for neuropathologically established MSA remain unchanged. For a clinical MSA diagnosis a new category of clinically established MSA is introduced, aiming for maximum specificity with acceptable sensitivity. A category of clinically probable MSA is defined to enhance sensitivity while maintaining specificity. A research category of possible prodromal MSA is designed to capture patients in the earliest stages when symptoms and signs are present, but do not meet the threshold for clinically established or clinically probable MSA. Brain magnetic resonance imaging markers suggestive of MSA are required for the diagnosis of clinically established MSA. The number of research biomarkers that support all clinical diagnostic categories will likely grow. Conclusions This set of MDS MSA diagnostic criteria aims at improving the diagnostic accuracy, particularly in early disease stages. It requires validation in a prospective clinical and a clinicopathological study. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society MDS Criteria for the Diagnosis of Multiple System Atrophy
Bibliografia:Funding source for study
none.
Glenda Halliday is supported by a National Health and Medical Research Council (NHMRC) Senior Leadership Fellowship. Roy Freeman has received consulting fees and stock options from CND Life Sciences and Inhibikase Therapeutics. Werner Poewe has received personal fees for consultancy from Alterity, Affiris, Biogen, Lundbeck, and Takeda in relation to drug development programs targeting multiple system atrophy. Other authors declare financial disclosures/conflicts of interest related to this work.
Financial Disclosures/Conflicts of Interest concerning the research related to the manuscript
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
Financial Disclosures/Conflicts of Interest concerning the research related to the manuscript: Glenda Halliday is supported by a National Health and Medical Research Council (NHMRC) Senior Leadership Fellowship. Roy Freeman has received consulting fees and stock options from CND Life Sciences and Inhibikase Therapeutics. Werner Poewe has received personal fees for consultancy from Alterity, Affiris, Biogen, Lundbeck, and Takeda in relation to drug development programs targeting multiple system atrophy. Other authors declare financial disclosures/conflicts of interest related to this work.
Funding source for study: none.
ISSN:0885-3185
1531-8257
1531-8257
DOI:10.1002/mds.29005